bjd12717-sup-0001-DataS1-TableS1-S2-FigS1.docxWord document272K

Data S1. Materials and methods.

Table S1. List of the genes investigated.

Table S2. Nucleotide sequences of the primers employed in RT-PCR; the size of the amplified products is indicated in base-pairs (bp).

Fig S1. Combination of troglitazone and 5-AZA-dC treatment enhances the sensitivity to apoptosis and reduces cell growth in cutaneous T-cell lymphoma lines. (A) HUT102 peroxisome proliferator-activated receptor gamma (PPARγ)-positive cells have a higher sensitivity totroglitazone (TZD) than HUT78 PPARγ-negative cells. (B) The combined treatment of TZD and 5-AZA-dC synergistically reduces cell proliferation in a time-and dose-dependent manner. TZD enhances cell growth inhibition at the higher 5-AZA-dC concentration, as a consequence of the PPARγ full reactivation, while the selective antagonist (GW 9662) reduces the effects especially in HUT78 cells. (C) Cell cycle distribution by fluorescence-activated cell sorting FACS analysis shows that TZD and 5-AZA-dC in combination determines a significant increase in the number of cells in the sub-G0-G1 phase (apoptotic phase). *Significant at 0.05 level; **significant at 0.01 level.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.